MetaCap

Actuate Therapeutics (ACTU) vs Context Therapeutics (CNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Context Therapeutics (CNTX) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 85.3% versus a loss of 96.4%. Context Therapeutics is the larger company by market cap ($14.7 million vs $13.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-96.43%CNTX-85.32%
+224%+56%-112%
Nov 21, 20251 yearNov 20, 2026
ACTU-97.41%CNTX-93.87%
+43%-30%-104%
Aug 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus CNTX key metrics
MetricACTUCNTX
Share price$0.2253$0.16
Market cap$13.60M$14.70M
1-day change+5.38%-5.10%
YTD return-96.32%-89.12%
1-year return-96.43%-85.32%
5-year return—-96.86%
EPS (TTM)$-0.76$-0.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.23M$-36.12M
52-week high$7.90$3.62
52-week low$0.174$0.153
Distance from 52-week high-97.15%-95.58%
Analyst consensusnonenone
Avg. price target upside+5084.20%+2418.75%
Average volume807.24K1.42M
Shares outstanding60.38M91.88M
Employees1215
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CNTX has outperformed ACTU by 11.1 percentage points over the past year.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ACTU vs CNTX FAQ

Which is bigger, Actuate Therapeutics or Context Therapeutics?

Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $13.60M for Actuate Therapeutics (ACTU).

Which stock has performed better over the past year, ACTU or CNTX?

CNTX returned -85.32% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.

Are Actuate Therapeutics and Context Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons